- |||||||||| APS08 / Applied Pharmaceutical Sci
GR.APS.08: CVD and Pregnancy Outcomes (Zone 3) - Oct 7, 2024 - Abstract #AHA2024AHA_8813;
Poster Professor: Lahouaria Hadri (MOUNT SINAI SCHOOL MEDICINE) Abstract presensations on CVD and Pregnancy Outcomes.
- |||||||||| APS08 / Applied Pharmaceutical Sci
PL.APS.08: Potpourri of Behavioral Interventions (Zone 3) - Oct 7, 2024 - Abstract #AHA2024AHA_8558;
This session will include projects focused on a variety of behavioral interventions, including nutritional education, peer-group exergaming, and community-health volunteers. Poster Professor: Damon L Swift (University of Virginia)
- |||||||||| APS08 / Applied Pharmaceutical Sci
IN.APS.08: TAVR: Which Valve, Which Patient? (Zone 4) - Oct 7, 2024 - Abstract #AHA2024AHA_8514;
This collection of abstracts highlights technical considerations in the performance of transcatheter aortic valve replacement with an emphasis on valve selection and different patient cohorts. Poster Professor: Christine Chung (University of Washington)
- |||||||||| APS08 / Applied Pharmaceutical Sci
HF.APS.08: Heart Failure Potpourri (Zone 1' Science & Technology Hall) - Oct 7, 2024 - Abstract #AHA2024AHA_8438;
New data on ventricular form and function among individuals suffering from heart failure and associated cardiomyopathies. Poster Professor: Larry Alexander Allen (UNIVERSITY COLORADO DENVER)
- |||||||||| APS08 / Applied Pharmaceutical Sci
GE.APS.08: Omics of Heart Failure (Zone 1' Science & Technology Hall) - Oct 7, 2024 - Abstract #AHA2024AHA_8383;
This session highlights the newest research utilizing omics and systems biology approaches to understand heart failure. Poster Professor: Harm J Bogaard (VU UNIV MEDICAL CENTER)
- |||||||||| APS08 / Applied Pharmaceutical Sci
AC.APS.08: The Intersection of Non-cardiac Pathologies and ACS (Zone 4) - Oct 7, 2024 - Abstract #AHA2024AHA_8228;
Poster Professor: Harm J Bogaard (VU UNIV MEDICAL CENTER) Poster session addressing the management of ACS in patients with other significant non-cardiac diseases.
- |||||||||| APS08 / Applied Pharmaceutical Sci
CH.APS.08: Pediatric Cardiac Surgery (Zone 2) - Oct 7, 2024 - Abstract #AHA2024AHA_7872;
Poster session addressing the management of ACS in patients with other significant non-cardiac diseases. Posters featuring science and outcomes in pediatric cardiac surgery Poster Professor: Andrew Goldstone (Columbia University)
- |||||||||| APS08 / Applied Pharmaceutical Sci
AT.APS.08: All Things Atherosclerosis (Zone 1' Science & Technology Hall) - Oct 7, 2024 - Abstract #AHA2024AHA_7817;
This session covers a range of topics related to atherosclerotic cardiovascular disease. Poster Professor(s): Robert C Bauer (Columbia University)Hong S Lu (UNIVERSITY KENTUCKY)
- |||||||||| APS08 / Applied Pharmaceutical Sci
EP.APS.08: Clinical Prediction, Prognosis, and Decision-Making (Zone 3) - Oct 7, 2024 - Abstract #AHA2024AHA_7590;
Attendees gain insights into cutting-edge research and practical implications for enhancing clinical decision-making processes in diverse healthcare settings. Poster Professor: Fares Alahdab (University of Missouri)
- |||||||||| APS08 / Applied Pharmaceutical Sci
EA.APS.08: Unusual Cases and Rare Circumstances! (Zone 2) - Oct 7, 2024 - Abstract #AHA2024AHA_7557;
This session provides a series of unusual complications and case presentations and cardiac arrhythmias. Poster Professor: Rachel Kaplan (MUSC)
- |||||||||| APS03118 / Applied Pharmaceutical Sci
The development of APS03118, a potent next-generation RET inhibitor for treating RET-inhibitor-resistant patients. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5241;
APS03118 is a novel highly selective next-generation RET inhibitor that possesses potent in vitro and in vivo activity against a diverse range of RET alterations, including SFMs-mediated resistance. APS03118 has received IND approval and Fast Track Designation from FDA, and a first-in-human phase 1 trial for patients with RET-driven solid tumors with activating RET alterations is planned for 2022.
|
